Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04929483 is registered in ClinicalTrials.gov with 89bio, Inc. as lead sponsor.

NCT NCT04929483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04929483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
89bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2021
Completion date
October 8, 2024
Enrollment
222 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis